Valbiotis
Valbiotis develops nutrition solutions to prevent metabolic diseases and provides support for patients, including Valedia for type 2 diabetes.
Valbiotis develops nutrition solutions to prevent metabolic diseases and provides support for patients, including Valedia for type 2 diabetes.
Valbiotis is a biotechnology startup based in France, founded in 2014, with a primary focus on developing nutrition solutions to prevent metabolic diseases. The company's flagship product, Valedia, targets type 2 diabetes and provides support for patients. Valbiotis adopts a unique approach by developing a new class of health nutrition products utilizing plant-based terrestrial and marine resources. With its commitment to scientific innovation, the company aims to address unmet medical needs related to metabolic and cardiovascular diseases. The startup has received a significant €9.70M Post-IPO Equity investment on 09 November 2022, reflecting investor confidence in its innovative approach and product pipeline. Valbiotis has established its presence across France with three sites in Périgny, La Rochelle, and Riom, in addition to a subsidiary in Quebec City, Canada. Overall, Valbiotis' strategic focus on developing preventive solutions for metabolic diseases, coupled with its recent substantial investment, positions the company as a noteworthy player in the biotechnology industry with potential for significant growth and impact on public health.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | €9.70M | - | 09 Nov 2022 | |
| Post-IPO Equity | €15.00M | - | 15 Apr 2021 | |
| Seed Round | €1.80M | 1 |
|
31 Mar 2016 |
No recent news or press coverage available for Valbiotis.
We care about your data, and we'd love to use cookies make your experience better.
